Genascence is a clinical-stage biotechnology company developing gene therapy products specifically targeting osteoarthritis, a leading cause of disability and chronic pain. Their approach aims to provide effective treatments for this prevalent condition, reducing the risk of opioid addiction associated with chronic pain management.
Funding
$10.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Osteoarthritis is a prevalent condition and a leading cause of disability and chronic pain, often managed with treatments that carry a risk of opioid addiction. Current therapeutic options do not effectively address the underlying causes of the disease, leading to progressive joint damage and limited long-term relief.
Solution
Genascence is developing gene therapy products designed to target the root causes of osteoarthritis and provide long-lasting relief. Their lead candidate, GNSC-001, is a genetic medicine that delivers a gene to the affected joint, promoting the sustained expression of IL-1Ra, a potent inhibitor of IL-1. By blocking IL-1, a key mediator of inflammation and cartilage destruction in osteoarthritis, GNSC-001 aims to reduce pain, improve joint function, and slow disease progression. A Phase 1 clinical trial demonstrated that a single intra-articular injection of GNSC-001 resulted in elevated IL-1Ra levels in the synovial fluid for up to a year, with no serious adverse events related to gene delivery. The FDA has granted Fast Track designation to GNSC-001, and the company is planning to initiate a Phase 2b/3 clinical trial to further evaluate its clinical efficacy.
Target Audience
The primary target audience includes individuals suffering from knee osteoarthritis and the clinicians who treat them, including orthopedic surgeons, rheumatologists, and pain management specialists.
Features
- GNSC-001: A gene therapy product blocking interleukin 1 (IL-1) for the treatment of knee osteoarthritis
- Targets the source of pain and cartilage destruction
- Sustained IL-1Ra expression in synovial fluid after a single administration
- Demonstrated safety and tolerability in Phase 1 clinical trials
- Fast Track Designation from the FDA